C3-Luc Cells Are an Excellent Model for Evaluation of Cellular Immunity following HPV16L1 Vaccination.

C3-Luc Cells Are an Excellent Model for Evaluation of Cellular Immunity following HPV16L1 Vaccination.

C3 and TC-1 are the two model cell lines most commonly used in studies of vaccines and drugs against human papillomavirus (HPV) infection. Because C3 cells contain both the HPV16 E and L genes, but TC-1 cells contain only the HPV16 E genes, C3 cells are usually used as the model cell line in studies...

Full description

Bibliographic Details
Main Authors:	Li-Li Li, He-Rong Wang, Zhi-Yi Zhou, Jing Luo, Xiao-Li Wang, Xiang-Qian Xiao, Yu-Bai Zhou, Yi Zeng
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4763794?pdf=render

Similar Items

Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.
by: Lili Gan, et al.
Published: (2014-01-01)

Jean-Luc Darlix: Renaissance scientist and retrovirologist <it>par excellence</it>
by: Cohen Eric A, et al.
Published: (2011-07-01)

Cellular immune responses to human papillomavirus (HPV) type 16 at the cervix of women with HPV-associated squamous intraepithelial neoplasia
by: Milner, Michelle
Published: (2014)

Enhancing immunogenicity of HPV16 E7 DNA vaccine by conjugating codon-optimized GM-CSF to HPV16 E7 DNA
by: Yi-Pin Chen, et al.
Published: (2021-07-01)

Identification of the Offspring of Vegfr2-luc Transgenic Mouse
by: Qinghua ZHOU, et al.
Published: (2011-05-01)

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
by: Matthew P Morrow, et al.
Published: (2016-01-01)

Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor
by: Li S, et al.
Published: (2019-10-01)

Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor
by: Wang S, et al.
Published: (2017-09-01)

A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model
by: Fei Yin, et al.
Published: (2017-06-01)

The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors
by: Ana C. R. Moreno, et al.
Published: (2018-08-01)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
by: Anna Godi, et al.
Published: (2015-01-01)

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate.
by: Karen Nieto, et al.
Published: (2012-01-01)

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali.
by: Ibrahima Téguété, et al.
Published: (2017-01-01)

Human Papillomavirus Infection and Vaccination: Awareness and Knowledge of HPV and Acceptability of HPV Vaccine among Mothers of Teenage Daughters in Weihai, Shandong, China.
by: Yang Yu, et al.
Published: (2016-01-01)

Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.
by: Daning Wang, et al.
Published: (2015-01-01)

HPV - immune response to infection and vaccination
by: Stanley Margaret
Published: (2010-10-01)

Human Papillomavirus (HPV) Vaccine Uptake and the Willingness to Receive the HPV Vaccination among Female College Students in China: A Multicenter Study
by: Dingyun You, et al.
Published: (2020-01-01)

Immune cellular response to HPV: current concepts
by: Maria Alice Guimarães Gonçalves, et al.

Rapid detection of high-risk HPV16 and HPV18 based on microchip electrophoresis
by: Zhaoxuan Fan, et al.
Published: (2020-08-01)

Brucella abortus RB51 lipopolysaccharide influence as an adjuvant on the therapeutic efficacy of HPV16 L1 and HPV16 E7 DNA vaccines
by: Masoumeh Shirmohammadi, et al.
Published: (2021-01-01)

Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67.
by: Zigui Chen, et al.
Published: (2011-01-01)

HPV-Vaccines
Published: (2023)

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model
by: Sebastian Kruse, et al.
Published: (2019-01-01)

Antitumor Immunity Induced by Genetic Immunization with Chitosan Nanoparticle Formulated Adjuvanted for HPV-16 E7 DNA Vaccine
by: Alireza Tahamtan, et al.
Published: (2018-12-01)

Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine
by: Iwona Hus, et al.
Published: (2015-04-01)

Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina
by: Joaquín Víctor González, et al.
Published: (2020-12-01)

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda.
by: Edward Kumakech, et al.
Published: (2016-01-01)

Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among male baccalaureate students in Hong Kong.
by: Teris Cheung, et al.
Published: (2018-01-01)

THE RISK OF MISCARRIAGE FOLLOWING IMMUNIZATION OF THE BIVALENT HUMAN PAPILLOMAVIRUS (HPV) - 16/18 VACCINE: A BAYESIAN APPROACH
by: FANG, TIAN
Published: (2013)

Immunizing against Anogenital Cancer: HPV Vaccines.
by: Cloe S Pogoda, et al.
Published: (2016-05-01)

Antimetastatic Effects of Ganoderma lucidum Polysaccharide Peptide on B16-F10-luc-G5 Melanoma Mice With Sleep Fragmentation
by: Haocheng Xian, et al.
Published: (2021-07-01)

HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix
by: Wenbo Long, et al.
Published: (2018-05-01)

Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.
by: Shiwen Peng, et al.
Published: (2015-01-01)

Effect of an educational intervention on HPV knowledge and attitudes towards HPV and its vaccines among junior middle school students in Chengdu, China
by: Chun-Rong Liu, et al.
Published: (2019-05-01)

Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine
by: Ssu-Hsueh Tseng, et al.
Published: (2021-09-01)

Knowledge and Acceptance of HPV and the HPV Vaccine in Young Men and Their Intention to be Vaccinated
by: Jasper, Brenda Renee
Published: (2014)

Genetic variants of <it>NOXA</it> and <it>MCL1</it> modify the risk of HPV16-associated squamous cell carcinoma of the head and neck
by: Zhou Ziyuan, et al.
Published: (2012-05-01)

Disruption of HPV16-E7 by CRISPR/Cas System Induces Apoptosis and Growth Inhibition in HPV16 Positive Human Cervical Cancer Cells
by: Zheng Hu, et al.
Published: (2014-01-01)

Isolation of anti-idiotype minor capsid Human papillomavirus type 16 (HPV 16 L2) IgY from egg yolk as immunogen of HPV vaccine
by: EKA NONENG NAWANGSIH, et al.
Published: (2017-07-01)

GARDASIL. QUADRIVALENT RECOMBINANT VACCINE AGAINST HPV (6, 11, 16, 18 TYPES)
by: article editorial
Published: (2007-04-01)